Laura Chico
Stock Analyst at Wedbush
(3.95)
# 614
Out of 5,182 analysts
264
Total ratings
47.34%
Success rate
11.73%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics | Reiterates: Outperform | $7 | $2.60 | +169.23% | 4 | Apr 15, 2026 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $39 → $44 | $40.50 | +8.64% | 13 | Apr 14, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $37 → $31 | $13.73 | +125.78% | 11 | Apr 8, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $151 → $166 | $127.68 | +30.01% | 12 | Apr 7, 2026 | |
| PHVS Pharvaris | Maintains: Outperform | $41 → $42 | $28.58 | +46.96% | 9 | Apr 7, 2026 | |
| ANRO Alto Neuroscience | Maintains: Neutral | $22 → $21 | $24.52 | -14.36% | 6 | Apr 2, 2026 | |
| PEPG PepGen | Maintains: Outperform | $9 → $5 | $1.54 | +224.68% | 14 | Apr 1, 2026 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $12 → $13 | $4.54 | +186.34% | 6 | Mar 20, 2026 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $36 → $38 | $34.03 | +11.67% | 11 | Mar 18, 2026 | |
| EWTX Edgewise Therapeutics | Reiterates: Outperform | $32 | $31.58 | +1.33% | 12 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $55.24 | +14.05% | 11 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 → $58 | $25.81 | +124.72% | 3 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $17 | $7.92 | +114.65% | 5 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $103 | $87.39 | +17.86% | 14 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $24.98 | -3.92% | 4 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $9.14 | +53.17% | 2 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $18 | $40.94 | -56.03% | 15 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $6 → $1 | $0.36 | +175.71% | 7 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $5.95 | +219.33% | 16 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $95 → $130 | $344.82 | -62.30% | 12 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $25 | $24.10 | +3.73% | 15 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $178 → $187 | $184.38 | +1.42% | 20 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $30 | $19.87 | +50.98% | 10 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $37.69 | -12.44% | 9 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $8.94 | +101.34% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.79 | +84.70% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $88 | $8.63 | +919.70% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $12.53 | -60.10% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $53.18 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $6.40 | -21.88% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $9.88 | +1,403.04% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $10.06 | +7,057.06% | 1 | Jan 19, 2018 |
Ovid Therapeutics
Apr 15, 2026
Reiterates: Outperform
Price Target: $7
Current: $2.60
Upside: +169.23%
Travere Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $39 → $44
Current: $40.50
Upside: +8.64%
Viridian Therapeutics
Apr 8, 2026
Maintains: Outperform
Price Target: $37 → $31
Current: $13.73
Upside: +125.78%
Neurocrine Biosciences
Apr 7, 2026
Maintains: Outperform
Price Target: $151 → $166
Current: $127.68
Upside: +30.01%
Pharvaris
Apr 7, 2026
Maintains: Outperform
Price Target: $41 → $42
Current: $28.58
Upside: +46.96%
Alto Neuroscience
Apr 2, 2026
Maintains: Neutral
Price Target: $22 → $21
Current: $24.52
Upside: -14.36%
PepGen
Apr 1, 2026
Maintains: Outperform
Price Target: $9 → $5
Current: $1.54
Upside: +224.68%
Larimar Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $12 → $13
Current: $4.54
Upside: +186.34%
Stoke Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $36 → $38
Current: $34.03
Upside: +11.67%
Edgewise Therapeutics
Mar 17, 2026
Reiterates: Outperform
Price Target: $32
Current: $31.58
Upside: +1.33%
Mar 16, 2026
Maintains: Outperform
Price Target: $64 → $63
Current: $55.24
Upside: +14.05%
Mar 16, 2026
Maintains: Outperform
Price Target: $43 → $58
Current: $25.81
Upside: +124.72%
Mar 12, 2026
Maintains: Outperform
Price Target: $14 → $17
Current: $7.92
Upside: +114.65%
Mar 12, 2026
Maintains: Outperform
Price Target: $80 → $103
Current: $87.39
Upside: +17.86%
Mar 9, 2026
Reiterates: Outperform
Price Target: $24
Current: $24.98
Upside: -3.92%
Mar 6, 2026
Maintains: Outperform
Price Target: $12 → $14
Current: $9.14
Upside: +53.17%
Feb 25, 2026
Maintains: Neutral
Price Target: $20 → $18
Current: $40.94
Upside: -56.03%
Feb 24, 2026
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.36
Upside: +175.71%
Feb 23, 2026
Reiterates: Outperform
Price Target: $19
Current: $5.95
Upside: +219.33%
Feb 20, 2026
Maintains: Underperform
Price Target: $95 → $130
Current: $344.82
Upside: -62.30%
Feb 17, 2026
Reiterates: Neutral
Price Target: $25
Current: $24.10
Upside: +3.73%
Feb 10, 2026
Maintains: Neutral
Price Target: $178 → $187
Current: $184.38
Upside: +1.42%
Dec 11, 2025
Maintains: Outperform
Price Target: $31 → $30
Current: $19.87
Upside: +50.98%
Dec 11, 2025
Maintains: Neutral
Price Target: $23 → $33
Current: $37.69
Upside: -12.44%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $8.94
Upside: +101.34%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.79
Upside: +84.70%
Apr 11, 2024
Maintains: Outperform
Price Target: $104 → $88
Current: $8.63
Upside: +919.70%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $12.53
Upside: -60.10%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $53.18
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $6.40
Upside: -21.88%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $9.88
Upside: +1,403.04%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $10.06
Upside: +7,057.06%